A Review of Chronobiology-Based Drug Delivery Systems

Aniqua T. S. Sheikh[1], Kundan J. Singh[2], Gule Samreen Kazi[3], Rupali S. Suryawanshi[4], Tiksha P. Yerne[5], Riya P. Ghate [6,] Avantika V. Pofare[7], Pratik D. Dhokne[8], Swapnil S. Tirmanwar [9]
[1,2,3] *Assistant Professor, The Royal Gondwana College of Pharmacy, Shankarpur, Nagpur*
[4]*Student, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule*
[5,6] *Student, Priyadarshini J. L College of Pharmacy, Nagpur*
[7]*Student, Nagpur College of Pharmacy, Nagpur*
[8]*Research scholar Priyadarshini J. L College of Pharmacy, Nagpur*
[9]*Research scholar*

***Abstract*—The field of chronopharmacology explores the impact of biological rhythms on drug efficacy and safety, leading to the emergence of chronobiology-based drug delivery systems. These systems optimize therapeutic outcomes by aligning drug release with the body's natural biological cycles, enhancing efficacy while minimizing adverse effects. This review provides an overview of chronopharmacology principles, existing drug delivery technologies, and advancements in chronotherapeutics. Various delivery approaches, including pulsatile, programmable, and stimuli-responsive systems, are discussed in the context of conditions such as cardiovascular diseases, asthma, and cancer. Challenges and prospects in developing chronobiology-driven drug formulations are also explored, highlighting their potential in personalized medicine.**

***Index Terms*—Chronopharmacology, Chronotherapy, Drug Delivery System, Biological Rhythms, Circadian Cycle, Pulsatile Release, Personalized Medicine, Chronobiology**

I. INTRODUCTION

Extensive research is being conducted globally to develop novel drug delivery systems. In conventional drug therapy, medication is released immediately upon administration, leading to a rapid increase in plasma drug concentration, sometimes exceeding toxic levels. The primary goal of drug discovery is to maximize therapeutic efficacy while minimizing adverse effects. Advances in pharmaceutical technology have transformed drug therapy. Although sustained and controlled-release systems have been developed, biological systems do not always respond effectively to these methods. Additionally, such systems are not suitable for time-dependent administration of hormones and other drugs that are susceptible to metabolic degradation and resistance development [1]. The human body functions as a dynamic, rhythmic system requiring specific drug concentrations at particular times within the circadian cycle. All physiological processes, from cellular activity to genetic expression, are temporally organized and synchronized [2]. Pulsatile drug delivery systems have been designed to address this need, releasing drugs in a controlled manner after a predetermined lag time, following the circadian rhythm of disease progression [3]. During this lag phase, no drug is released. This system is particularly beneficial for drugs, including proteins and peptides, that undergo extensive metabolic degradation. It also reduces drug resistance and adverse effects in chronic treatments by ensuring that the desired drug concentration is available at the required time [4,5]. Additionally, this method is advantageous for drugs with extensive first-pass metabolism and those targeted to specific sites in the intestinal tract.

Pulsatile drug delivery is gaining attention due to its ability to provide time- and site-specific drug release with precise dosage control. The system aligns drug release with the circadian rhythm, which regulates numerous physiological functions. Many acute and chronic diseases exhibit circadian variations in symptom onset and severity. The importance of these rhythms in health sciences has been increasingly recognized. Clinical chronobiology dates back to the

5th century when Caelius-Aurelianus documented nocturnal asthma, building on the work of Soranus of Ephesus in the 2nd century. Subsequent reports by Wirsung (1568), Castello (1616), and Floyer (1698) further contributed to this field [2].

The sleep-wake cycle is a key synchronizer for most humans, typically spanning from approximately 10:30 p.m. to 6:30 a.m., with daily activity commencing around 6:30 a.m. and lasting until 10:30 p.m. Pulsatile drug delivery falls under the field of "chronopharmaceutics," which integrates chronobiology and pharmaceutics. Chronobiology examines biological rhythms and their mechanisms, categorized into three types: circadian (approximately 24-hour cycles), ultradian (more than one cycle per 24 hours), and infradian (less than one cycle per 24 hours) [6,7]. The suprachiasmatic nucleus, located above the optic nerve at the hypothalamus's base, regulates these cycles and coordinates nearly all bodily functions [8].

Chronotherapy has been applied in clinical practice since the 1960s [7]. Circadian rhythms influence gastrointestinal, liver, kidney, and other physiological processes, affecting the pharmacokinetics, duration of drug effects, efficacy, and adverse reactions [8]. Diseases targeted for pulsatile drug delivery include asthma, arthritis, duodenal ulcers, cancer, cardiovascular diseases, diabetes, hypercholesterolemia, and neurological disorders, all of which exhibit strong circadian rhythms [10].

For instance, asthma is characterized by airway inflammation leading to hyperresponsiveness in the lower respiratory tract. Nocturnal asthma exacerbates symptoms due to increased airway resistance at night. During the day, antigen exposure triggers the release of pro-inflammatory mediators, culminating in inflammation, smooth muscle bronchospasm, excessive mucus production, and airway obstruction over several hours. Since bronchoconstriction follows a circadian pattern, asthma is a suitable candidate for chronotherapy [11,12].

Allergic rhinitis symptoms, including sneezing, nasal congestion, and red, itchy eyes, peak in the morning before breakfast and are least frequent in the afternoon. This condition progresses through an early phase (occurring within minutes) and a late phase (manifesting 12–16 hours later). The early phase results from the release of histamine, prostaglandins, and cytokines, while the late phase involves leukocyte infiltration, leading to nasal congestion and inflammation [11].

Pain management is a key therapeutic concern, yet inadequate pain relief remains a widespread issue. Pain perception follows a circadian rhythm, with thresholds varying throughout the day. For example, in arthritis, circadian variations exist in plasma levels of C-reactive protein and interleukin-6. Additionally, different opioid peptides, such as substance P and cytokines, play roles in nociception. Research indicates that brain concentrations of substance P peak at night, while endogenous opioid peptide levels are highest in the morning and decline throughout the day. Osteoarthritis patients tend to experience less pain in the morning and more pain at night, whereas rheumatoid arthritis patients typically have peak pain in the morning, which subsides during the day. Similar circadian patterns have been observed in gastroesophageal reflux disease and renal colic [8,13,14].

The timing of analgesic administration depends on the pain's nature and duration. Nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, anticonvulsants, and tricyclic antidepressants are prescribed based on pain type and circadian rhythm considerations. Additionally, duodenal ulcer patients experience peak gastric acid secretion at night, necessitating nighttime drug administration for optimal efficacy [8,14,15].

Chronobiological research has also shed light on cancer treatment. Circadian fluctuations affect blood flow to tumor sites, influencing chemotherapy efficacy. Studies on acute lymphoblastic leukemia indicate that evening administration of chemotherapy drugs, such as 6-mercaptopurine and methotrexate, doubles survival rates compared to morning dosing. Similar results have been observed with 5-fluorouracil (5-FU), where circadian delivery minimizes cytotoxic effects [8,10,17,18,19].

Cardiovascular diseases also follow circadian patterns. Capillary resistance, vascular reactivity, and platelet aggregation peak in the morning, increasing the risk of myocardial infarction and sudden cardiac death. Blood pressure, heart rate, and catecholamine levels exhibit significant circadian variations, influencing cardiac arrhythmias. Pharmacokinetics and pharmacodynamics of medications such as β-blockers and calcium channel blockers are affected by the time of administration [1,21,22,23].

In diabetes management, insulin secretion follows a pulsatile pattern, with circadian variations affecting glucose regulation. Hormones such as cortisol and epinephrine influence insulin action, contributing to early-morning and late-afternoon insulin resistance [24].

Hypercholesterolemia treatment is also time-dependent. Cholesterol synthesis peaks at night, with HMG-CoA reductase activity being highest during this period. Consequently, statins are more effective when taken in the evening [25].

Circadian rhythms influence numerous biological processes, including sleep, epilepsy, Alzheimer's disease, Parkinson's disease, coagulation, and immune responses. Sleep disorders, such as delayed sleep-phase syndrome, result from circadian disruptions. Epilepsy also exhibits circadian fluctuations, with seizure susceptibility linked to biological rhythms [7,26,27,28]. Alzheimer's patients experience alterations in motor activity and circadian temperature regulation, linked to dysfunctions in the suprachiasmatic nucleus [29]. Parkinson's disease affects blood pressure regulation and autonomic function, though circadian involvement remains unclear [30].

Hemostasis follows circadian patterns, with variations in blood coagulation factors and fibrinolytic activity influencing thrombotic and hemorrhagic events. The highest blood clotting activity occurs in the morning, correlating with increased cardiovascular events during this time [31].

Infectious diseases also display circadian and seasonal variations. Fever due to bacterial infections peaks in the evening, whereas viral infections are more common in the morning. Influenza outbreaks are prevalent in winter, and several infectious diseases exhibit seasonal peaks [32].

Finally, the central nervous system, endocrine glands, immune system, and other physiological functions follow complex rhythmic patterns, emphasizing the importance of chronotherapy in optimizing treatment outcomes [33].

II. SYSTEM BASED ON OSMOSIS

Such a system consists of a capsule coated with a semipermeable membrane. An insoluble plug, an osmotically active agent, and a drug formulation are kept inside the capsule. When the capsule shell comes in contact with GI fluid the semipermeable membrane allows the entry of gastric fluid. As a consequence, the plug swells and creates osmotic pressure. When this pressure exceeds the tensile strength of the membrane it bursts out and the time taken for rupture of the membrane is known as lag time. After lag

III. PH

A particular pH is used as a triggering point of drug release from such a delivery system. That device can be made using pH-dependent polymer in such a manner that the drug will be released after reaching the particular surrounding pH of the device. Glucose glucose-induced insulin delivery system for a diabetic patient is made based on this stimulus. Glucose oxidase catalyzes the oxidation of glucose to gluconic acid which leads to a decrease in the pH of the medium. The lowering of pH is used as a trigger. [1,16,33,46,48,52]

OROS® technology

Chronset™ is a proprietary OROS® delivery system that reproducibly delivers a bolus drug dose in a time- or site-specific manner to the gastrointestinal tract [79]. It is nothing but an osmosis-based system. The active pharmaceutical is kept in a reservoir surrounded by a semipermeable membrane laser drilled with a delivery orifice and formulated into a tablet.

IV. CURRENT SITUATION AND FUTURE SCOPE

Nowadays pulsatile drug delivery is gaining popularity. The prime advantage of this drug delivery is that the drug is released when necessity comes. As a result, chance of development of drug resistance which is seen in conventional and sustained release formulations can be reduced. Furthermore, some anticancer drugs are very toxic. These drugs pose hazardous problems in conventional and sustained-release therapies. Now many FDA-approved chronotherapeutic drugs are available in the market.

V. CONCLUSION

Chronopharmacology and pulsatile drug delivery systems represent a paradigm shift in modern medicine, aligning drug administration with the body's natural biological rhythms. By leveraging circadian variations in disease pathology, these approaches

enhance therapeutic efficacy while minimizing adverse effects. Extensive research has demonstrated the benefits of time-specific drug delivery in managing conditions such as asthma, arthritis, cardiovascular diseases, cancer, diabetes, and neurological disorders. The integration of chronotherapy into clinical practice requires further advancements in pharmaceutical formulations, personalized medicine, and patient-specific treatment strategies. Developing innovative drug delivery technologies, including nanoparticles, polymers, and programmable devices, will be critical in optimizing chronotherapeutic interventions. Additionally, a deeper understanding of molecular chronobiology will help refine treatment regimens, ensuring that drug administration aligns with physiological processes. As research in this field continues to evolve, chronopharmaceutics holds immense potential to revolutionize drug therapy, improving patient outcomes and reducing the burden of chronic diseases. Future studies should focus on refining chronotherapeutic strategies, exploring genetic influences on circadian rhythms, and developing patient-friendly delivery systems to maximize adherence and effectiveness.

REFERENCE

[1] Asim Sattw, a Mandal, Nikhil Biswas, Kazimasud Karim, Arijit Guha, Sugata Chatterjee, Mamata Bahera, Keto Usetuo Kuotsu. Drug delivery system based on chronobiology—A review, Journal of Controlled Release Volume 147, Issue 3, 1 November 2010, Pages 314-325

[2] B.C. Youan, Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J. Control. Release 98 (2004) 337–353. [

[3] B. Lemmer, Chronobiology, drug-delivery and chronotherapeutics, Adv. Drug Deliv. Rev. 59 (2007) 825–827.

[4] T. Bussemer, N.A. Peppas, R. Bodmeier, Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system, Eur. J. Pharm. Biopharm. 56 (2003) 261–270.

[5] F. Pozzi, P. Furlani, A. Gazzaniga, S.S. Davis, I.R. Wilding, The time clock system: a new oral dosage form for fast and complete release of drug after a predetermined lag time, J. Control. Release 31 (1994) 99–108.

[6] B.C. Youan, Chronopharmaceutical drug delivery systems: Hurdles, hype or hope? Adv. Drug Deliv. Rev. 62 (2010) 898–903.

[7] G.D. Rosenberg, D.J. Simmons, Rhythmic dentinogenesis in the rabbit incisor: circadian, ultradian and infradian periods, Calcified Tissue Int. 32 (2006) 29–44.

[8] M.H. Smolensky, N.A. Peppas, Chronobiology, drug delivery and chronopharmaceutics, Adv. Drug Deliv. Rev. 59 (2007) 828–851.

[9] Z. Khan, V. Pillay, Y.E. Choonara, L.C. du Toit, Drug delivery technologies for chronotherapeutic applications, Pharm. Dev. Technol. 14 (2009) 602–612.

[10] M.H. Smolensky, G.E. D'Alonzo, Biologic rhythms and medicines, Am. J. Med. 85 (1988) 34–46.

[11] V.S. Belgamwar, M.V. Gaikwad, G.B. Patil, S. Surana, Pulsatile drug delivery system, Asian J. Pharm. (July-September 2008) 141–145.

[12] M.H. Smolensky, B. Lemmer, A.E. Reinberg, Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma, Adv. Drug Deliv. Rev. 59 (2007) 852–882.

[13] R.J. Martin, S. Banks-Schlegel, Chronobiology of asthma, Am. J. Respir. Crit. Care Med. 158 (1998) 1002–1007.

[14] B. Bruguerolle, G. Labrecque, Rhythmic pattern in pain and their chronotherapy, Adv. Drug Deliv. Rev. 59 (2007) 883–895.

[15] T. Saitohl, Y. Watanabe, Y. Kubo, M. Shinagawa, K. Otsuka, S.A. Ohkawa, T. Watanabe, Intragastric acidity and circadian rhythm, Biomed. Pharmacother. 55 (2000) s138–s141.

[16] J.G. Moore, F. Halberg, Circadian rhythm of gastric acid secretion in men with active duodenal ulcer, Dig. Dis. Sci. 31 (1986) 1185–1191.

[17] C. Svanes, R.B. Sothern, H. Sorbye, Rhythmic patterns in the incidence of peptic ulcer perforation over 5.5 decades in Norway, Chronobiol. Int. 15 (1998) 241–264.

[18] F. Levi, C. Focan, A. Karaboue, V. de la Valette, D. Focan-Henrard, B. Baron, F. Kreutz, S. Giacchetti, Implications of circadian clocks for the rhythmic delivery of cancer therapeutics, Adv. Drug Deliv. Rev. 59 (2007) 1015–1035.

[19] Altinok, F. Levi, A. Goldbeter, A cell cycle automation model for probing circadian patterns

of anticancer drug delivery, Adv. Drug Deliv. Rev. 59 (2007) 1036–1053.
[20] K. Hori, M. Suzuki, S. Tanda, S. Saito, M. Shinozaki, Q.H. Zhang, Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II-induced hypertension, Cancer Res. 52 (1992) 912–916.
[21] K. Hori, Q.H. Zhang, H.C. Li, S. Saito, Y. Sato, Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow, Int. J. Cancer 65 (1996) 360–364.
[22] G.H. Tofler, D. Brezinski, A.I. Schafer, C.A. Czeisler, J.D. Rutherford, S.N. Willich, R.E. Gleason, G.H. Williams, J.E. Muller, Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death, N Engl J. Med. 316 (1987) 1514–1518.
[23] F. Portaluppi, R.C. Hermida, Circadian rhythms in cardiac arrhythmias and opportunities for their chronotherapy, Adv. Drug Deliv. Rev. 59 (2007) 940–951.
[24] F. Portaluppi, B. Lemmer, Chronobiology and chronotherapy of ischemic heart disease, Adv. Drug Deliv. Rev. 59 (2007) 952–965.
[25] W. Waldhäusl, Circadian rhythms of insulin needs and actions, Diab. Res. Clin. Pract. 6 (1989) S17–S24.
[26] P.J.H. Jones, D.A. Schoeller, Evidence for diurnal periodicity in human cholesterol synthesis, J. Lipid Res. 31 (1990) 667–673.
[27] V.M. Kumar, Sleep and sleep disorders, Indian J. Chest Dis. Allied Sci. 50 (2008) 129–136.
[28] Hofstra, A.W. de Weerd, how to assess circadian rhythm in humans: a review of literature, Epilepsy Behav. 13 (2008) 438–444.
[29] Poirel, M. Ennaji, Circadian aspects of epileptic behavior in comparative psychophysiology, Psychol. Rep. 68 (1991) 783–801. [29] L. Volicer, D.G. Harper, B.C. Manning, R. Goldstein, A. Satlin, Sundowning and circadian rhythms in Alzheimer's disease, Am. J. Psychiatry 158 (2001) 704–711.
[30] Bruguerolle, N. Simon, Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function, Clin. Neuropharmacol. 25 (2002) 194–201.
[31] Haus, Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention, Adv. Drug Deliv. Rev. 59 (2007) 966–984.
[32] Beauchamp, G. Labrecque, Chronobiology and chronotoxicology of antibiotics and aminoglycosides, Adv. Drug Deliv. Rev. 59 (2007) 896–903.
[33] Haus, Chronobiology in the endocrine system, Adv. Drug Deliv. Rev. 59 (2007) 985–1014.
[34] E. Haus, Chronobiology in the endocrine system, Adv. Drug Deliv. Rev. 59 (2007) 985–1014.
[35] M. Barzegar-Jalali, M. Siyahi-Shadbad, Design and evaluation of delayed release osmotic capsule of acetaminophen, Iran J. Pharma. Sci. Spring 2 (2006) 65–72.
[36] Linkwitz, J.A. Magruder, S. Merrill, osmotically driven delivery device with an expandable orifice for pulsatile delivery effect, US Patent 5,318,558 (1994).
[37] S.M. Balaban, J.B. Pike, J.P. Smith, C.A. Baile, Osmotically driven delivery devices with pulsatile effect, US Patent 5,209,746 (1993).
[38] K. Niwa, T. Takaya, T. Morimoto, K. Takada, Preparation and evaluation of time-controlled release capsule made of ethyl cellulose for colon delivery of drugs, J. Drug Target. 3 (1995) 83–89.
[39] S. Arora, J. Ali, A. Ahuja, S. Baboota, J. Qureshi, Pulsatile drug delivery systems: an approach for controlled drug delivery, Indian J. Pharm. Sci. (May-June 2006) 295–300.
[40] T. Bussemer, A. Dashevsky, R. Bodmeier, A pulsatile drug delivery system based on rupturable coated hard gelatin capsules, J. Control. Release 93 (2003) 331–339.
[41] Krogel, R. Bodmeier, Pulsatile drug release from an insoluble capsule body controlled by an erodible plug, Pharm. Res. 15 (1998) 474–481.
[42] Krogel, R. Bodmeier, Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system, Pharm. Res. 16 (1999) 1424–1429.
[43] Mohamad, A. Dashevsky, pH-independent pulsatile drug delivery system based on hard gelatin capsules and coated with aqueous dispersion Aquacoat ECD, Eur. J. Pharm. Biopharm. 64 (2006) 173–179.
[44] F. Pozzi, P. Furlani, A. Gazzaniga, S.S. Davis, The TIME CLOCK system: a new oral dosage form for fast and complete release of drug after predetermined lag time, J. Control. Release 31 (1994) 99–108.

[45] I.R. Wilding, S.S. Davis, F. Pozzi, P. Furlani, A. Gazzaniga, Enteric-coated timed release systems for colonic targeting, Int. J. Pharm. 111 (1994) 99–102.

[46] Gazzaniga, P. Iamartino, G. Maffione, M.E. Sangalli, Oral delayed-release system for a colonic specific delivery, Int. J. Pharm. 2 (1994) 77–83.

[47] Maroni, L. Zema, M. Cerea, M.E. Sangalli, Oral pulsatile drug delivery systems, Expert Opin. Drug Deliv. 2 (2005) 855–871.

[48] M.E. Sangalli, A. Maroni, L. Zema, C. Busetti, F. Giordano, A. Gazzaniga, In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery, J. Control. Release 73 (2001) 103–110.

[49] U. Conte, A. La Manna, P. Colombo, Tablet for pharmaceutical use able to release active substances at successive times, US Patent 4,865,849 (1989).

[50] U. Conte, P. Giunchedi, L. Maggi, M.E. Sangalli, A. Gazzaniga, P. Colombo, A. La Manna, Ibuprofen delayed release dosage forms: a proposal for the preparation of an in vitro/in vivo pulsatile system, Eur. J. Pharm. 38 (1992) 209–212.

[51] P. Roy, A. Shahiwala, Multiparticulate formulation approach to pulsatile drug delivery: Current perspectives, J. Control. Release 134 (2009) 74–80.

[52] T. Bussemer, R. Bodmeier, Multiparticulate pulsatile drug delivery systems, in: S. Benita (Ed.), Microencapsulation Methods and Industrial Applications Second Edition, CRC Press, Tyalor and Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742, 2006.

[53] Krogel, R. Bodmeier, Floating or pulsatile drug delivery systems based on coated effervescent cores, Int. J. Pharm. 187 (1999) 175–184. [54] P. Percel, K.S. Vishnupad, G.M. Venkatesh, Timed pulsatile drug delivery systems, US Patent No. 6,627,223B2 (2003).

[54] S. Narisawa, M. Nagata, Y. Hirakawa, M. Kobayashi, H. Yoshino, An organic acid-induced sigmoidal release system for oral controlled-release preparations. Part II: permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid, J. Pharm. Sci. 85 (1996) 184–188.

[55] S. Narisawa, M. Nagata, C. Danyoshi, H. Yoshino, K. Murata, Y. Hirakawa, K. Noda, An organic acid-induced sigmoidal release system for oral controlled-release preparations, Pharm. Res. 11 (1994) 111–116.

[56] R. Bodmeier, X. Guo, R.E. Sarabia, P. Skultety, the influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic polymer dispersions, Eudragit RS, RL 30D, Pharm. Res. 13 (1996) 52–56.

[57] K. Ishihara, M. Kobayashi, N. Ishimura, I. Shinohara, Glucose-induced permeation control of insulin through a complex membrane consisting of immobilized glucose oxidase and a poly(amine), Polym. J. 16 (1984) 625–631.

[58] Lalwani, D.D. Santani, Pulsatile drug delivery systems, Indian J. Pharm. Sci. (July-August 2007) 489–497.

[59] R. Yoshida, K. Sakai, T. Okano, Y. Sakurai, Drug release profiles in the shrinking process of thermoresponsive poly (N-isopropylacrylamide-co-alkyl methacrylate) gels, Ind. Eng. Cham. Res. 31 (1992) 2339–2345.

[60] Y. Kaneko, K. Sakai, A. Kikuchi, R. Yoshida, Y. Sakurai, T. Okano, Influence of freely mobile grafted chain length on dynamic properties of comb-type grafted poly (N-isopropyl acrylamide) hydrogels, Macromolecules 28 (1995) 7717–7723.

[61] K.S. Oha, S.K. Hana, Y.W. Choia, J.H. Leea, J.Y. Leeb, S.H. Yuka, Hydrogen-bonded polymer gel and its application as a temperature-sensitive drug delivery system, Biomaterials 25 (2004) 2393–2398.

[62] J. Akimoto, M. Nakayama, K. Sakai, T. Okano, Temperature-induced intracellular uptake of thermoresponsive polymeric micelles, Biomacromolecules 10 (2009) 1331–1336. [64] N.S. Satarkar, J.Z. Hilt, Magnetic hydrogel nanocomposites for remote controlled pulsatile drug release, J. Control. Release 130 (2008) 246–251.

[63] R. Langer, Polymer systems for controlled release of macromolecules, immobilized enzyme medical bioreactors, and tissue engineering, in: J. Wei, J.L. Anderson, K.B. Bischoff, M.M. Denn, J.H. Seinfeld, G. Stephanopoulos (Eds.), Advances in

Chemical Engineering, Academic Press Limited, 24-28 Oval Road. London NW1 7DX, 1994.
[64] S. Hu, T. Liu, D. Liu, S. Chen, Controlled pulsatile drug release from a ferrogel by a high-frequency magnetic field, Macromolecules 40 (2007) 6786–6788.
[65] O. Saslawski, C. Weingarten, J.P. Benoit, P. Couvreur, magnetically responsive microspheres for the pulsed delivery of insulin, Life Sci. 42 (1988) 1521–1528.
[66] C.S. Kwok, P.D. Mourad, L.A. Crum, B.D. Ratner, Self-assembled molecular structures as ultrasonically-responsive barrier membranes for pulsatile drug delivery, J. Biomed. Mater. Res. A 57 (2001) 151–164.
[67] Lanting, J. Barfett, Encapsulated calcium carbonate suspensions: a drug delivery vehicle sensitive to ultrasound disruption, MJM 9 (2006) 108–110.
[68] Supersaxo, J.H. Kou, P. Teitelbaum, R. Maskiewicz, Preformed porous microspheres for controlled and pulsed release of macromolecules, J. Control. Release 23 (1993) 157–164.
[69] S. Murdan, Electro-responsive drug delivery from hydrogels, J. Control. Release 92 (2003) 1–17.
[70] I.C. Kwon, Y.H. Bae, S.W. Kim, Electrically erodible polymer gel for controlled release of drugs, Nature 354 (1991) 291–293.
[71] S. Kagatani, T. Shinoda, Y. Konno, M. Fukui, T. Ohmura, Y. Osada, Electroresponsive pulsatile depot delivery of insulin from poly(dimethylaminopropylacrylamide) gel in rats, J. Pharm. Sci. 86 (2000) 1273–1277.
[72] S.Y. Kim, Y.M. Lee, Drug release behavior of electrical responsive poly (vinyl alcohol)/poly(acrylic acid) IPN hydrogels under an electric stimulus, J. Appl. Polym. Sci. 74 (1999) 1752–1761.
[73] S.R. Sershen, S.L. Westcott, N.J. Halas, J.L. West, Temperature-sensitive polymer nanoshell composites for photothermally modulated drug delivery, J. Biomed. Mater. Res. 51 (2000) 293–298.
[74] S.R. Sershen, S.L. Westcott, N.J. Halas, J.L. West, An optomechanical nanoshellpolymer composite, Appl. Phys. B 73 (2001) 379–381.
[75] R.D. Averitt, D. Sarkar, N.J. Halas, Plasmon resonance shifts of Au-coated Au2S nanoshells: insight into multicomponent nanoparticle growth, Phys. Rev. Lett. 78 (1997) 4217–4222.
[76] K.Y. Lee, M.C. Peters, K.W. Anderson, D.J. Mooney, Controlled growth factor release from synthetic extracellular matrices, Nature 408 (2000) 998–1000.
[77] R. Conley, S.K. Gupta, G. Sathyan, Clinical spectrum of the osmotic-controlled release oral delivery system (OROS*), an advanced oral delivery form, Curr. Med. Res. Opin. 22 (2006) 1879–1892.
[78] B.C. Youan, Overview of chronopharmaceutics, in: B.C. Youan (Ed.), Chronopharmaceutics: Science and Technology for Biological Rhythm Guided Therapy and Prevention of Diseases, John Wiley & Sons, Inc, 111 River Street, Hoboken, NJ, 2009.
[79] L.M. Prisant, J.G. Devane, J. Butler, A steady-state evaluation of the bioavailability of chronopharmaceutic oral drug absorption system verapamil PM after night time dosing versus immediate-acting verapamil dosed every 8 h, Am. J. Ther. 7 (2000) 345–351.
[80] U. Conte, L. Maggi, Modulation of the dissolution profiles from Geomatrix® multilayer matrix tablets containing drugs of different solubility, Biomaterials 17 (1996) 889–896.
[81] W.E. Katstra, R.D. Palazzolo, C.W. Rowe, B. Giritlioglu, P. Teung, M.J. Cima, Oral dosage forms fabricated by Three-Dimensional Printing™, J. Control. Release 66 (2000) 1–9.
[82] C.W. Rowe, W.E. Katstra, R.D. Palazzolo, B. Giritlioglu, P. Teung, M.J. Cima, Multimechanism oral dosage forms fabricated by three-dimensional printing™, J. Control. Release 66 (2000) 11–17.
[83] J.N. Staniforth, A.R. Baichwal, TIMERx®: novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract, Expert Opin. Drug Deliv. 2 (2005) 587–595.
[84] Horter, J.B. Dressman, Influence of physicochemical properties on the dissolution of drugs in the gastrointestinal tract, Adv. Drug Deliv. Rev. 46 (2001) 75–87.
[85] R. Mahey, T. Bersot, Drug therapy for hypercholesterolemia and dyslipidemia, in: J. Hardman, L. Limbird, A. Gilman (Eds.), Goodman and Gilman's The Pharmacological

Basis of Therapeutics, McGraw-Hill, New York, 2001.

[86] J.T. Santini Jr., M.J. Cima, R. Langer, A controlled-release microchip, Nature 397 (1999) 335–338. [89] J.T. Santini Jr., A.C. Richards, R. Scheidt, M.J. Cima, R. Langer, Microchips as controlled drug-delivery devices, Angew. Chem. Int. Ed. 39 (2000) 2396–2407.

[87] http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No= 021121&TABLE1=OB_Rx. [91] http://www.medicalnewstoday.com/articles/59546.php.